Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA)
- PMID: 7459892
Item in Clipboard
Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA)
Cancer Treat Rep.
1980 Oct-Nov.
Abstract
N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of greater than or equal to 6 g/m2/course, mucositis occurring at doses of greater than or equal to 7.5 g/m2/course, and skin rash occurring at doses greater than 9 g/m2/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m2/course is recommended for a phase II trial.
Similar articles
-
Phase I trial of PALA.Cancer Treat Rep. 1980;64(12):1301-5. Cancer Treat Rep. 1980. PMID: 7471120
-
Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1909-12. Cancer Treat Rep. 1979. PMID: 526923
-
Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.Cancer Treat Rep. 1980 Apr-May;64(4-5):617-24. Cancer Treat Rep. 1980. PMID: 6448687
-
Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.Cancer Res. 1988 Aug 15;48(16):4441-54. Cancer Res. 1988. PMID: 3293772 Review. No abstract available.
-
The role of low-dose PALA in biochemical modulation.Pharmacol Ther. 1990;48(3):371-80. doi: 10.1016/0163-7258(90)90055-7. Pharmacol Ther. 1990. PMID: 2084707 Review.
Cited by
-
A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.Cancer Chemother Pharmacol. 1991;28(1):51-4. doi: 10.1007/BF00684956. Cancer Chemother Pharmacol. 1991. PMID: 2040033 Clinical Trial.
-
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.Cancer Chemother Pharmacol. 1987;19(1):80-3. doi: 10.1007/BF00296262. Cancer Chemother Pharmacol. 1987. PMID: 3815730